Trial reportClinical and experimental nephrology2018
A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B
Trial report in Clinical and experimental nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysis.Journal of nephrology · 2020Pooled it
- Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Article
- A Randomized Controlled Study of Efficacy and Safety of Accelerated Versus Standard Hepatitis B Vaccination in Patients With Advanced CKD.Kidney international reports · 2024Article
- Partial recovery of SARS-CoV-2 immunity after booster vaccination in renal transplant recipients.Clinical immunology communications · 2023Article
- Lassa Virus Countermeasures.Current topics in microbiology and immunology · 2023Article
- Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals.Cell · 2022Article
- Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients.The Journal of clinical investigation · 2021Article
- Viral hepatitis update: Progress and perspectives.World journal of gastroenterology · 2021Review
- Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24Frontiers in immunology · 2021Article
- Management Approaches to Hepatitis B Virus Vaccination Nonresponse.Gastroenterology & hepatology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDialysis patients have a suboptimal response to hepatitis B (HBV) vaccination. This study aimed to compare the immunogenicity of two vaccines: the third-generation Sci-B-Vac™ vs. the second-generation Engerix B
methodsEighty-six patients were assigned to vaccine (Sci-B-Vac™ or Engerix B
resultsEach group had 43 patients. Seroconversion was 69.8% with Engerix B
conclusionsThis study suggests comparable immunogenicity for both vaccines. Thus, we cannot reject the null hypothesis that there is no difference in seroconversion by vaccine type. It is noteworthy that naïve patients were vaccinated with a standard dose of Sci-B-Vac™, while Engerix B
Indexed as
Identifiers
28456864What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.